Psychemedics Corp.

As of December 31, 2024, Psychemedics Corp. carries a market capitalization of 13.69M, placing it among publicly traded companies globally. Its enterprise value stands at 13.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2024, Psychemedics Corp. has 6.11M shares outstanding.

These figures are as of December 31, 2024. The price-to-sales ratio is 0.67, and the price-to-book ratio stands at 2.67.

As of December 31, 2024, Psychemedics Corp. trades at an EV/EBITDA multiple of 71.46 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.44M versus a market cap of 13.69M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2024, Psychemedics Corp. maintains a current ratio of 1.82, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended December 31, 2024, Psychemedics Corp. posted a negative return on equity (ROE) of -31.54, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -18.03, reflecting losses generated across the asset base. The company generates approximately 175,367.48 in revenue per employee across its workforce of 112.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended December 31, 2024, Psychemedics Corp. recorded an income tax benefit of -55,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.92M and -1.86M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on June 26, 2026, Psychemedics Corp.'s stock has gained approximately 10.79% over the past 52 weeks. The 50-day moving average sits at 1.83, while the 200-day moving average is 2.07.

Over the twelve months ended December 31, 2024, Psychemedics Corp. generated 19.69M in revenue and converted that into -1.86M in net income, yielding earnings per share of -0.32. EBITDA reached 188,000.00, while operating income came in at -1.89M.

As of December 31, 2024, Psychemedics Corp. holds 1.42M in cash and equivalents against 1.17M in total debt, resulting in a net debt position of -1.21M. Total book value stands at 5.13M, with working capital of 2.23M providing operational flexibility.

Psychemedics Corp. produced 929,000.00 in operating cash flow over the twelve months ended December 31, 2024. After subtracting -87,000.00 in capital expenditures, free cash flow totaled 842,000.00 - equivalent to 0.14 per share.

Over the twelve months ended December 31, 2024, Psychemedics Corp. posted a gross margin of 36.07, reflecting its pricing power and cost economics. The operating margin of -9.62 and net profit margin of -9.45 provide insight into operational efficiency.

Over the twelve months ended December 31, 2024, Psychemedics Corp. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.36, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 10.15, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Psychemedics Corp. shareholders.

Psychemedics Corp.'s most recent stock split took place on August 1, 2002 with a 4:1 split ratio.

As of December 31, 2024, Psychemedics Corp. has an Altman Z-Score of 1.38, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.